Literature DB >> 26149376

Isocitrate Dehydrogenase Genes.

Antonis Tsamaloukas.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26149376      PMCID： PMC4496479          DOI： 10.3238/arztebl.2015.0372a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Authors:  Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens
Journal:  Oncologist       Date:  2014-02-21

Review 2.  The diagnosis and treatment of cholangiocarcinoma.

Authors:  Arndt Vogel; Henning Wege; Karel Caca; Björn Nashan; Ulf Neumann
Journal:  Dtsch Arztebl Int       Date:  2014-10-31       Impact factor: 5.594

Review 3.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

4.  Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Authors:  Darrell R Borger; Lipika Goyal; Thomas Yau; Ronnie T Poon; Marek Ancukiewicz; Vikram Deshpande; David C Christiani; Hannah M Liebman; Hua Yang; Hyeryun Kim; Katharine Yen; Jason E Faris; A John Iafrate; Eunice L Kwak; Jeffrey W Clark; Jill N Allen; Lawrence S Blaszkowsky; Janet E Murphy; Supriya K Saha; Theodore S Hong; Jennifer Y Wo; Cristina R Ferrone; Kenneth K Tanabe; Nabeel Bardeesy; Kimberly S Straley; Sam Agresta; David P Schenkein; Leif W Ellisen; David P Ryan; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2014-01-29       Impact factor: 13.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.